Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
65.96
+1.41 (+2.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxcyte Inc
< Previous
1
2
3
4
Next >
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Recap: Vaxcyte Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Via
Benzinga
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
December 07, 2023
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Via
Benzinga
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Jacks Lee to Board of Directors
November 28, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 09, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at Upcoming Investor Conferences
October 31, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
October 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
July 11, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
May 03, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.